KALA BIO, Inc. (KALA) Q2 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, my name is Chantal and I will be your conference operator today. At this time, I would like to welcome everyone to the Cali Pharmaceuticals second quarter 2022 financial results conference call. As a reminder, today's conference call is being recorded. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you'd like to withdraw your question, please press star one again. Thank you. Hannah Deresiewicz from Stern Investor Relations, you may begin your conference. Thank you, Operator, and thank you all for participating in today's call. Joining me from the company are Mark Iwiki, Chairman and Chief Executive Officer, Kim Brazel, Head of R&D and Chief Medical Officer, and Mary Remus, Chief Financial Officer. Darius Karabi, our Chief Business Officer, will also be joining us for the Q&A portion of today's call. During this call, we will be referring to non-GAAP financial measures, which are not prepared in accordance with generally accepted accounting principles. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures is available in our press release issued today, which can also be found on our website. On this call, we will make certain comments about college future expectations, plans, and prospects that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements will include statements regarding the development program and market potential of KPI 012, plan productions and operating expenses, and the sufficiency of our cash resources. These an...